Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting

Phase 3

RMC-6236Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor:

Revolution Medicines, Inc.

Code:

NCT06625320

Conditions

Pancreatic Cancer

PDAC

PDAC - Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RMC-6236

Gemcitabine

nab-paclitaxel

Irinotecan

Liposomal irinotecan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Revolution Medicines, Inc. on 2025-04-08.